Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply
- PMID: 32852833
- DOI: 10.1111/apt.15992
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply
Comment on
-
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.Aliment Pharmacol Ther. 2020 Jul;52(1):196-204. doi: 10.1111/apt.15741. Epub 2020 May 26. Aliment Pharmacol Ther. 2020. PMID: 32452564
-
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B.Aliment Pharmacol Ther. 2020 Sep;52(5):911-912. doi: 10.1111/apt.15966. Aliment Pharmacol Ther. 2020. PMID: 32852812 No abstract available.
References
REFERENCES
-
- Gattani M, Ingle M, Chauhan S, et al. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:911-912.
-
- Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196-204.
-
- Kim G-A, Lim Y-S, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945-952.
-
- Kim G-A, Han S, Choi GH, et al. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51:1169-1179.
-
- Liaw YF, Chu CM. Immune tolerance phase of chronic hepatitis B. Gastroenterology. 2017;152:1245-1246.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical